Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D
The experimentally established mechanism targets of Cianidanol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 7/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.80 |
| ▸ | MEN1 | O00255 | 4/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.80 |
| ▸ | MAPT | P10636 | 4/20 | 0.80 |
| ▸ | RECQL | P46063 | 4/20 | 0.80 |
| ▸ | SNCA | P37840 | 4/20 | 0.80 |
| ▸ | GAA | P10253 | 3/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.80 |
| ▸ | APEX1 | P27695 | 3/20 | 0.80 |
| ▸ | PKM | P14618 | 3/20 | 0.80 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.80 |
| ▸ | RAD52 | P43351 | 3/20 | 0.80 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.80 |
| ▸ | ALPL | P05186 | 2/20 | 0.80 |
| ▸ | POLB | P06746 | 2/20 | 0.80 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cianidanol SCHEMBL7538738 | 0.91 | BACE1 (0.76) | BACE1KDM4EMEN1KMT2AHSD17B10 | |
| Cianidanol SCHEMBL27997178 | 0.91 | BACE1 (0.76) | BACE1KDM4EMEN1KMT2AHSD17B10 | |
| Cianidanol SCHEMBL144001 | 0.91 | BACE1 (0.76) | BACE1KDM4EMEN1KMT2AHSD17B10 | |
| Catechin SCHEMBL7198386 | 0.91 | BACE1 (0.76) | BACE1KDM4EMEN1KMT2AHSD17B10 | |
| (-)-Epicatechin SCHEMBL19971115 | 0.91 | BACE1 (0.76) | BACE1KDM4EMEN1KMT2AHSD17B10 | |
| Catechin SCHEMBL9311459 | 0.91 | BACE1 (0.76) | BACE1KDM4EMEN1KMT2AHSD17B10 | |
| Cianidanol SCHEMBL28276939 | 0.91 | BACE1 (0.80) | BACE1KDM4EMEN1KMT2AHSD17B10 | |
| Cianidanol SCHEMBL28276937 | 0.91 | BACE1 (0.80) | BACE1KDM4EMEN1KMT2AHSD17B10 | |
| Cianidanol SCHEMBL27852538 | 0.91 | BACE1 (0.88) | BACE1KDM4EMEN1KMT2AHSD17B10 | |
| Cianidanol SCHEMBL28529009 | 0.91 | BACE1 (0.97) | BACE1KDM4EMEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9463195-B2 | Dissolution of amyloid fibrils by flavonoids and other compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-10-11 | — | — | US | disclosed |
| US-20100048510-A1 | DISSOLUTION OF AMYLOID FIBRILS BY FLAVONOIDS AND OTHER COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-25 | — | — | US | disclosed |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
| WO-2008076351-A2 | DISSOLUTION OF AMYLOID FIBRILS BY FLAVONOIDS AND OTHER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | BACE1 741/4885KDM4E 3739/4885MEN1 3749/4885 |
| US-20100048510-A1 | DISSOLUTION OF AMYLOID FIBRILS BY FLAVONOIDS AND OTHER COMPOUNDS | B2M, APP, BACE2 | BACE1 4/4885KDM4E 3921/4885MEN1 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.